Day five of bionano's next-generation cytogenomics symposium: saphyr identifies structural variants that may predispose to severe covid-19 illness

San diego, jan. 18, 2021 (globe newswire) -- bionano genomics, inc. (nasdaq: bngo) announced that the last day of its five-day next-generation cytogenomics symposium featured presentations by members of the covid-19 host genome structural variant (sv) consortium using the saphyr® system for optical genome mapping (ogm) to analyze the genomes of patients with severe covid-19 disease. the presentations by scientists and clinicians from leading hospitals and research institutions in europe and the us showed that saphyr was able to detect structural variants that may predispose to severe or mild covid-19 disease, which had not been identified previously by large studies using next-generation sequencing (ngs) or array-based methods to analyze genomic variation.
BNGO Ratings Summary
BNGO Quant Ranking